CAPTRUST Financial Advisors
ABCL icon

CAPTRUST Financial Advisors’s AbCellera Biologics ABCL Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-750
Closed -$16K – 4618
2021
Q2 		$16K Buy
750
+40
+6% +$1.1K ﹤0.01% 3253
2021
Q1 		$24K Buy
+710
New +$28.3K ﹤0.01% 2878

Other funds holding ABCL

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

CAPTRUST Financial Advisors's ABCL Position: Q3 2021 in Review

CAPTRUST Financial Advisors sold out of AbCellera Biologics (ABCL) in Q3 2021, closing a stake of 750 shares — an estimated $16K sold.

CAPTRUST Financial Advisors first reported a position in ABCL in Q1 2021 and held it in 2 quarters. The position peaked at $24K in Q1 2021. 116 funds tracked by Wall St. Rank hold ABCL as of Q3 2021.

  • CAPTRUST Financial Advisors reported no remaining AbCellera Biologics position as of Q3 2021 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 750 AbCellera Biologics shares in Q3 2021, an estimated $16K.
  • CAPTRUST Financial Advisors first reported a position in AbCellera Biologics in Q1 2021 and held it in 2 quarters.
  • CAPTRUST Financial Advisors's AbCellera Biologics position peaked at $24K in Q1 2021.
  • 116 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2021.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2021, filed 16 Nov 2021.